EVNIN LUKE 4
4 · Werewolf Therapeutics, Inc. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Werewolf Therapeutics (HOWL) Director Luke Evnin Sells 157,084 Shares
What Happened
Luke Evnin, a director of Werewolf Therapeutics, sold 157,084 shares of HOWL on June 29, 2026. The reported weighted-average price was $0.30 per share for total proceeds of about $47,125. The shares were sold in multiple transactions at prices ranging from $0.2703 to $0.33.
Key Details
- Date of transaction: 2026-06-29. Weighted-average price: $0.30; price range: $0.2703–$0.33.
- Total shares sold: 157,084; total proceeds ≈ $47,125.
- Breakdown of shares sold by entity (per filing): 16,830 by MPM Asset Management LLC; 106,262 by MPM BioVentures 2014, L.P.; 7,087 by MPM BioVentures 2014(B), L.P.; 3,657 by MPM Asset Management Investors BV2014 LLC; 23,248 by MPM Oncology Innovations Fund, L.P.
- Shares held after the sales (per filing): 15,341 (AM LLC); 96,873 (BV 2014); 6,459 (BV 2014(B)); 3,332 (AM BV2014); 21,194 (MPM OIF).
- Sale executed pursuant to a Rule 10b5-1 trading plan dated March 26, 2026. The filer disclaims beneficial ownership except to the extent of his pecuniary interest in the funds/entities involved.
- Filing date and Period of Report: 2026-06-29. No late filing is indicated in the report.
Context
These sales were of shares held by investment vehicles and were made under a pre-established 10b5-1 plan, which is a common mechanism for scheduled insider sales. Sales do not necessarily indicate the insider’s view of the company’s prospects; purchases are generally more informative about insider sentiment.
Insider Transaction Report
Form 4
EVNIN LUKE
Director
Transactions
- Sale
Common Stock
[F1][F2][F3][F4][F5]2026-06-29$0.30/sh−157,084$47,125→ 143,199 total(indirect: See Footnotes)
Footnotes (5)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- [F2]The shares were sold as follows: 16,830 by MPM Asset Management LLC ("AM LLC"), 106,262 by MPM BioVentures 2014, L.P. ("BV 2014"), 7,087 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 3,657 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 23,248 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2703 to $0.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- [F5]The shares are held as follows: 15,341 by AM LLC, 96,873 by BV 2014, 6,459 by BV 2014(B), 3,332 by AM BV2014 and 21,194 by MPM OIF.
Signature
/s/ Luke Evnin|2026-06-29